SLS (SELLAS Life Sciences Group, Inc.) Company Cash Funds

Public company logo of SELLAS Life Sciences Group (SLS)

The cash position of SELLAS Life Sciences (SLS), as reported by the GURU.Markets platform, demonstrates transparent control over vaccine development despite a high dependence on investments. The 0.14 mark reflects the current state of resources for leukemia immunotherapy and the acquisition of exclusive rights. However, the absence of stable product revenue forces the business to rely exclusively on external capital injections to maintain viability.

SLS - SELLAS Life Sciences Company Liquid Assets over the range 07/04/2022 - 11/21/2026

Summary analytical data breakdowns for SELLAS Life Sciences Group (SLS)

- business market valuation indicators:
Fundamental valuation:SLS sellaslifesciences.com
Brand item of sellaslifesciences.com

For the long-term investor, the financial stability of SELLAS Life Sciences (SLS) is determined by its ability to fund capital-intensive development. This metric measures the volume of the most liquid assets, which serve as a defensive buffer against market volatility and inflationary depreciation. By analyzing the level of cash capital, one can assess the resource base for completing late-stage R&D of anti-tumor vaccines. A sufficient liquidity reserve confirms the operational stability of the business amid patent protection.

Main competitors

Company Cash Volume ONC|HALO - Company Cash Reserve|Revolution Medicines - Company Cash on Hand|Company Cash Volume Ascentage Pharma AAPG|CGON - Company Cash Funds|Company Total Cash Volume URGN|BCAX: Company Cash Volume|PSNL - Company Liquid Assets|ERAS (Erasca Inc) - Company Cash Volume|Company Cash Reserve Delcath Systems Inc DCTH|Company Cash Funds YmAbs (YMAB)|Company Liquid Assets Aura Bio|Company Cash Volume CADL (Candel Therapeutics Inc.)|accuray.com (ARAY) - Company Cash Reserve|actuatetherapeutics.com - Company Cash Volume|Company Cash Reserve Citius Oncology|HURA: Company Cash Volume|Company Total Cash Volume TARA (Protara)|FATE (fatetherapeutics.com) - Company Cash Volume|Company Cash Reserve Aadi Bioscience WHWK|Company Cash Volume TCRX|CSBR - Company Cash Reserve|XBiotech - Company Cash on Hand|CEL-SCI Corporation (CVM) - Company Cash Reserve|OSTX - Company Cash Funds|Company Cash Reserve Radiopharm Theranostics Ltd|ARTV (artivabio.com) - Company Cash on Hand|ANL (Adlai Nortye Ltd) - Company Cash Funds|Company Cash on Hand VERU|Tempest Therapeutics (TPST) - Company Liquid Assets|Company Cash Volume XLO|Company Cash on Hand Renovaro RENB|Company Cash Volume MURA (Mural Oncology PLC)|KAPA - Company Cash on Hand|OnKure Therapeutics - Company Cash Volume|w2.cytomed.sg - Company Total Cash Amount|Curis Corp (CRIS) - Company Cash Funds|Company Cash Reserve Apollomics Corp (APLM)|Company Cash Funds Tharimmune|Company Cash Volume advanbiomed.com|Company Cash Funds Genprex, Inc (GNPX)|Company Liquid Assets Calidi Biotherapeutics, Inc.|Company Cash Volume SBFM (Sunshine Biopharma Inc.)|XBIO - Company Cash on Hand|SLRX: Company Cash on Hand|Company Cash Balance PPBT (Purple Biotech Ltd.)|AONC: Company Cash Volume|Company Cash Reserve BeOne Medicines (BGNE)|Company Cash Funds Checkpoint Therapeutics, Inc.|Company Cash on Hand Elevation Oncology (ELEV)|Company Cash Funds iCAD Corp (ICAD)|Company Cash on Hand Ikena IKNA|Company Cash Volume NTBL (notablelabs.com)|VIRX - Company Cash on Hand|MOR: Company Cash on Hand|NAYA - Company Cash Volume|Ascentage Pharma (AAPGV) - Company Cash Funds